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Between February 26, 1981, and July 30, 1987, 36 pa-
tients underwent orthotopic liver transplantation for 
primary sclerosing cholangitis associated with ulcer-
ative colitis. Three of the 36 recipients died within 3 mo 
because of graft nonfunction or surgical complications. 
The other 33 (92%) lived for at least 1 yr. Two of the 33 
died after 12 and 14 mo, respectively, of recurrent cho-
langiocarcinoma that was not diagnosed before trans-
plantation. Four other patients died of recurrent liver 
failure (three cases) or immunoblastic sarcoma (one 
case) after 14, 21, 36 and 44 mo. Twenty-seven (75%) 
of the patients are still alive 23 to 81 mo after trans-
plantation. Two patients have been diagnosed as hav-
ing colorectal cancer 11 and 21 mo respectively, after 
transplantation, for an overall incidence of 5.6% (2 of 
36) and a corrected incidence of 6.5% (2 of 31) if the three 
early deaths and two later deaths caused by cholangio-
carcinomas are excluded. It is not known whether co-
lorectal malignancies were present but undetected at 
the time of transplantation or whether they developed 
afterward. It is clear that patients who undergo liver 
transplantation for primary sclerosing cholangitis as-
sociated with ulcerative colitis should have careful 
follow-up of the colon, including colonoscopy and mul-
tiple biopsies of the colorectal mucosa. Whether proc-
tocolectomy should be considered prophylactically af-
ter liver transplantation is an unresolved issue. (HEP-
ATOLOGY 1990;11:477-480.) 
Primary sclerosing cholangitis (PSC) is an uncom-
mon liver disease characterized by chronic inflamma-
tion and scarring of the intrahepatic or extrahepatic 
biliary tree, which leads to the development of second-
ary biliary cirrhosis (1-3). Orthotopic liver transplan-
tation (OLT) is the only curative treatment (4). PSC is 
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often associated with ulcerative colitis (UC) (1-3), 
which is known to carry an increased risk of colorectal 
cancer, especially when UC duration exceeds 10 yr 
(5-9). We report two patients who were diagnosed as 
having colorectal cancer after OLT for PSC associated 
with UC, and we review our experience with OLT for 
PSC accompanied by UC. 
PATIENTS AND METHODS 
Between February 26, 1981, and July 30, 1987, 580 adult 
primary OLTs were performed at the University Health Cen-
ter of Pittsburgh. The indication for transplantation in 74 
(12.8%) ofthese patients was PSC. UC also was diagnosed in 
43 (58.1 %) of the 74 recipients. Concomitant Crohn's disease 
was present in 6 (8.1%) of the 74 patients. Patients were 
considered to have primary sclerosing cholangitis when there 
were typical cholangiographical findings of the disease, 
pathological confirmation of the disease from the total hep-
atectomy specimen or the absence of a history or pathological 
evidence consistent with secondary biliary cirrhosis from 
other causes (4). 
Of the 43 patients who had PSC associated with DC, 7 
were excluded from the study because of previous right co-
lectomy for a Duke's class B carcinoma (one patient), total 
colectomy for UC (three patients) and proctocolectomy for UC 
(three patients). The ages of the 36 recipients without pre-
vious colorectal surgery ranged from 22 to 63 yr (mean = 
41 yr); 26 (72.2%) were men. UC duration before OLT was 3 
to 30 yr (mean = 14 yr). PSC had been diagnosed 2 to 14 yr 
(mean = 6 yr) before transplantation. UC preceded PSC in 
all but two patients. 
Three patients who died within 3 mo of transplantation 
from graft nonfunction or technical complications were ex-
cluded because meaningful colon studies were precluded. Two 
patients with previously undiagnosed cholangiocarcinomas 
in their native livers were also excluded. Transplantation was 
done successfully in these patients, but they died of tumor 
recurrence 12 and 14 mo later. Excluding these five cases, 31 
(86%) of the 36 recipients were eligible for long-term study. 
Four of the 36 died of recurrent liver failure (three patients) 
or immunoblastic sarcoma (one patient) after 14, 21, 36 and 
44 mo. Twenty-seven (75%) of the 36 are still alive after 23 
to 81 mo. The mean follow-up in the 31 patients admitted 
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TABLE 1. Ulcerative colitis in 31 patients who developed 
colorectal cancer after liver transplantation for 
sclerosing cholangitis 
Duration of UC Follow·up· No. patients 
(onset to OLT after OLT with 
inyr) (in rna) cancer/total 
<10 38 ± 14 0110 (0%) 
(21·58) 
10·20 46 ± 21 1114 (7.1%) 
(14-79) 
>20 45 ± 9 117 (14.3%) 
(32·54) 
TOTAL 43 ± 17 2/31 (6.5%) 
UC = ulcerative colitis; OLT = orthotopic liver transplantation. 
"Mean ± S.D. and range ( ). 
into the study group, including the four who died later, was 
45 mo (Table 1). 
Surgical techniques used during OLT were not influenced 
by the UC. During the time of case accrual, donor livers were 
preserved with Euro-Collins solution. Immunosuppression 
was done with cyclosporine and azathioprine, to which OKT3 
monoclonal antibody and! or azathioprine was added in a few 
cases (10). 
RESULTS 
Two (5.6%) ofthe 36 patients with PSC and UC were 
diagnosed as having colorectal cancer 11 and 21 mo· 
after OLT, respectively. Without the five patients who 
were excluded because of early death or recurrent cho-
langiocarcinoma, the corrected incidence of colorectal 
cancer was 2 (6.5%) of 31. The two patients with col-
orectal cancer both had histories of UC for 17 and 21 
yr, respectively. There were no colorectal cancers in 
patients whose UC had been present for less than 10 
yr (Table 1). 
Case Reports 
Case 1: A 48-yr-old white man with a 21-yr history 
of UC and PSC of 4 yr underwent OLT on August 19, 
1986. Colonoscopy in November 1985 showed no evi-
dence of ulceration, stricture or neoplasm in the colon 
or rectum. Multiple biopsy samples did not show ma-
lignancy. The course after transplantation was com-
plicated by acute cellular rejection, which required 
OKT3 monoclonal antilymphocyte globulin treatment, 
and by the transmission of human immunodeficiency 
virus from the donor organ (11). 
In February 1988 the patient noted constipation and 
incomplete defecation. Manual examination in May 
1988 revealed a rectal mass, and a barium-enema 
roentgenogram demonstrated circumferential stricture 
of the rectum. He underwent total proctocolectomy with 
end ileostomy on May 10,1988. There was no evidence 
at surgery of regional or distant metastases. Macro-
scopically, a 6-cm concentric stricture involved the rec-
tum from the dentate line upward 2 cm. Microscopi-
cally, sections from the stricture site demonstrated in-
filtrating, poorly differentiated adenocarcinoma with a 
marked lymphocytic inflammatory cell infiltrate. Can-
cer cells extended into the perirectal adipose tissue as 
well as nearby lymph nodes (Duke's class C). The pa-
tient's postoperative course was uneventful, and he has 
no evidence of recurrence 14 mo later. 
Case 2: A 44-yr-old white woman with a 17-yrhistory 
of UC and PSC of 6 yr underwent uneventful OLT on 
July 28, 1986. Pretransplant colonoscopy on April 24, 
1986, was normal except for colonic mucosal edema. 
Multiple biopsy samples did not show malignancy. The 
patient's course after transplantation was unremark-
able except for an episode of easily reversible acute 
cellular rejection. 
On July 1, 1987, she underwent colonoscopy for 
bloody diarrhea of 2 mo duration. Multiple colonic bi-
opsy samples obtained at that time revealed severe dys-
plasia of the entire colon, for which total proctocolec-
tomy with ileostomy was performed 11 mo after trans-
plant. The surgical specimen contained an indurated 
ulcer measuring 3.0 X 2.5 cm in the midsection of the 
transverse colon. The lesion was a well-differentiated 
adenocarcinoma with a prominent inflammatory cell 
infiltrate that extended through the colonic wall 
(Duke's class B) (Fig. 1). The patient remains well with-
out evidence of recurrence 24 mo after proctocolectomy. 
DISCUSSION 
Risk factors for the development of colorectal carci-
noma in patients with UC include prolonged duration 
or early onset of UC and extensive involvement along 
with severe dysplasia of the colonic mucosa (5-9). The 
incidence of colorectal cancer after 18 to 25 yr of UC 
has been reported to be from 1.4% to 34% (7-9). Our 
two patients are the first examples, to our knowledge, 
of this complication after OLT. Whether transplan-
tation contributed to or accelerated the malignant pro-
cess is open to speculation. 
It has been well documented that immunosuppres-
sion after transplantation leads to the development of 
certain forms of cancer (12, 13). Kidney transplant re-
cipients treated with azathioprine and prednisone have 
a higher than normal incidence of lymphoma, Kaposi's 
sarcoma and a variety of epithelial tumors, probably 
including colorectal carcinoma (12, 13). However, under 
immunosuppression with cyclosporine, incidence of 
carcinomas of the colon, rectum, lung, prostate and fe-
male breast has not increased much-if at all (14)-
although the risk of lymphoma and sarcoma remains 
high. 
In our two patients, pretransplant colorectal exam-
inations, including colonoscopy and biopsies, revealed 
no evidence of neoplasm or dysplasia. These studies 
were done 9 and 3 mo before transplantation. Unfor-
tunately, they were not repeated. Because the intervals 
between OLT and the development of colorectal cancer 
were only 11 and 21 mo in the two patients, respec-
tively, it is tempting to speculate that malignant trans-
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FIG. 1. (A) Section from proximal portion of tumor in Patient 2. Well-differentiated tubular adenocarcinoma extends into submucosa 
(arrows) (H & E, x 25). (B) High-power view of (A). Note prominent inflammatory cell infiltrate, predominant by lymphocytes and plasma 
cells (H & E, x 100). 
formation was stimulated by immunosuppression or 
other conditions of transplantation. However, there is 
no proof of this, and it is possible that the lesions were 
missed in the preoperative evaluation or developed be-
tween the examinations and the transplantation. Can-
cers arising in the colon or rectum involved with DC 
tend to be flat and to exhibit infiltrating growth. These 
qualities make it difficult, as in case 2, to establish the 
early diagnosis of colorectal cancer with the use of co-
lonoscopy alone (6). Our patients had DC for 17 and 21 
yr, respectively, increasing the risk of malignant de-
generation. 
It is clear that the changes caused by DC should be 
regarded as precancerous. Early detection of colorectal 
cancer in patients who have undergone OLT for PSC 
associated with DC should be attempted using semian-
nual colonoscopy with multiple mucosal biopsies and 
double-contrast barium enema (15). Our patients were 
an object lesson in that failure to be assiduous led to a 
delay in diagnosis. Whether proctocolectomy should be 
considered prophylactically after liver transplantation 
is an unresolved issue. 
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